Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Apr 23;137(17):1824–1841. doi: 10.1161/CIRCULATIONAHA.117.027799

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 The Authors.

Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

PMC Copyright notice

Figure 3. — miR-22 modulates VSMC proliferation and migration. VSMCs were transfected with miR-22 mimics, miR-22 inhibitor, or respective negative control miR (miRNA ctrl), followed by 24 hours of serum starvation. Subsequently, cells were treated with vehicle control (Ctrl), PDGF-BB (10 ng/mL), or serum (20%) for 48 hours and analyzed. A, RT-qPCR analysis confirmed miR-22 overexpression in VSMCs transfected with miR-22 mimics on PDGF-BB and serum treatment. B, RT-qPCR analysis confirmed that miR-22 expression was significantly inhibited in VSMCs transfected with miR-22 inhibitor in all treatments. C, BrdU assays revealed significantly decreased absorbance of VSMCs transfected with miR-22 mimics in all treatments, indicating decreased proliferation. D, Transwell migration assays showed significantly decreased migration of VSMCs transfected with miR-22 mimics under both PDGF-BB and serum stimulation. E, BrdU assays revealed significantly increased absorbance and therefore proliferation of VSMCs transfected with the miR-22 inhibitor on PDGF-BB and serum treatment. F, Transwell migration assays showed significantly increased migration of VSMCs transfected with the miR-22 inhibitor under both PDGF-BB and serum stimulation. Note: No or very few migrated cells were observed without cell chemoattractant in transwell migration assays; therefore, no control treatment is shown. Data and error bars represent the mean±SEM (n=3 in A; 4 in B, C, and E; or 5 in D and F). *P<0.05 (versus miRNA ctrl). ^#P<0.05 (versus Ctrl). BrdU indicates bromodeoxyuridine; miR-22, microRNA-22; PDGF-BB, platelet-derived growth factor BB; RT-qPCR, reverse transcription quantitative polymerase chain reaction; and VSMC, vascular smooth muscle cell.